Maic Audo Lin Sihombing

Diabetes mellitus is one of the common metabolic disorders with increasing prevalence during recent years with hyperglycemia as its characteristic. DM has been shown to be a state of free radicals over production resulted from hyperglycemia that can activate cellular signaling pathways transcription...

Full description

Saved in:
Bibliographic Details
Main Authors: Maic Audo Lin Sihombing, Sutiman B. Sumitro, Muhaimin Rifa'i
Format: Article
Language:English
Published: University of Brawijaya 2015-06-01
Series:Journal of Experimental Life Science
Subjects:
Online Access:https://jels.ub.ac.id/index.php/jels/article/view/161
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850260817136582656
author Maic Audo Lin Sihombing
Sutiman B. Sumitro
Muhaimin Rifa'i
author_facet Maic Audo Lin Sihombing
Sutiman B. Sumitro
Muhaimin Rifa'i
author_sort Maic Audo Lin Sihombing
collection DOAJ
description Diabetes mellitus is one of the common metabolic disorders with increasing prevalence during recent years with hyperglycemia as its characteristic. DM has been shown to be a state of free radicals over production resulted from hyperglycemia that can activate cellular signaling pathways transcription of factor NF-κB which stimulates the production of several inflammatory mediators andl lead to chronic inflammation. Chronic inflammation is implicated in β-cell damage and function and promotes apoptosis. EMSA Eritin is a polyherbal consisting of soy bean extracts, coconut water extract and red rice extract that assumed to be antidiabetic and anti-inflammatory. This study will assess the effectiveness of EMSA Eritin against inflammation in diabetes mellitus by measuring levels of NF-κB produced by immunocompetent cells in DM mice model. Streptozotocin 100 mg.kg-1 BW is used to induce diabetes mellitus in mice. Oral administration of EMSA Eritin was given for 14 days with dose of 0.3125 mg.g-1 BW, 3.125 mg.g-1 BW and 31.25 mg.g-1 BW. Data were analyzed using One-way ANOVA (p<0.05) and Duncan test using SPSS 16.0 for Windows. The results showed that EMSA Eritin can be used as an alternative therapy for the treatment of DM. The level of NF-κB in diabetic mice significantly decreased when the mice received EMSA Eritin.
format Article
id doaj-art-dbf4d6c504fd495b918e6a52b644652b
institution OA Journals
issn 2087-2852
2338-1655
language English
publishDate 2015-06-01
publisher University of Brawijaya
record_format Article
series Journal of Experimental Life Science
spelling doaj-art-dbf4d6c504fd495b918e6a52b644652b2025-08-20T01:55:33ZengUniversity of BrawijayaJournal of Experimental Life Science2087-28522338-16552015-06-01512430https://doi.org/10.21776/ub.jels.2015.005.01.05Maic Audo Lin SihombingMaic Audo Lin Sihombing0Sutiman B. Sumitro1Muhaimin Rifa'i2Universitas Brawijaya, Malang, IndonesiaUniversitas Brawijaya, Malang, IndonesiaUniversitas Brawijaya, Malang, IndonesiaDiabetes mellitus is one of the common metabolic disorders with increasing prevalence during recent years with hyperglycemia as its characteristic. DM has been shown to be a state of free radicals over production resulted from hyperglycemia that can activate cellular signaling pathways transcription of factor NF-κB which stimulates the production of several inflammatory mediators andl lead to chronic inflammation. Chronic inflammation is implicated in β-cell damage and function and promotes apoptosis. EMSA Eritin is a polyherbal consisting of soy bean extracts, coconut water extract and red rice extract that assumed to be antidiabetic and anti-inflammatory. This study will assess the effectiveness of EMSA Eritin against inflammation in diabetes mellitus by measuring levels of NF-κB produced by immunocompetent cells in DM mice model. Streptozotocin 100 mg.kg-1 BW is used to induce diabetes mellitus in mice. Oral administration of EMSA Eritin was given for 14 days with dose of 0.3125 mg.g-1 BW, 3.125 mg.g-1 BW and 31.25 mg.g-1 BW. Data were analyzed using One-way ANOVA (p<0.05) and Duncan test using SPSS 16.0 for Windows. The results showed that EMSA Eritin can be used as an alternative therapy for the treatment of DM. The level of NF-κB in diabetic mice significantly decreased when the mice received EMSA Eritin.https://jels.ub.ac.id/index.php/jels/article/view/161diabetes mellitusemsa eritinnf-κbros
spellingShingle Maic Audo Lin Sihombing
Sutiman B. Sumitro
Muhaimin Rifa'i
Maic Audo Lin Sihombing
Journal of Experimental Life Science
diabetes mellitus
emsa eritin
nf-κb
ros
title Maic Audo Lin Sihombing
title_full Maic Audo Lin Sihombing
title_fullStr Maic Audo Lin Sihombing
title_full_unstemmed Maic Audo Lin Sihombing
title_short Maic Audo Lin Sihombing
title_sort maic audo lin sihombing
topic diabetes mellitus
emsa eritin
nf-κb
ros
url https://jels.ub.ac.id/index.php/jels/article/view/161
work_keys_str_mv AT maicaudolinsihombing maicaudolinsihombing
AT sutimanbsumitro maicaudolinsihombing
AT muhaiminrifai maicaudolinsihombing